Ambey Laboratories
- P/E
- 19.68
Key Fundamentals
SMEFertilizers & AgrochemicalsChemicalsPrice-based figures as of · TTM
- ROCE
- 9.97%
- Debt to Equity
- 0.43
- EPS (TTM)
- ₹1.40
- Book Value
- ₹29.87
- Market Cap
- —
- P/E (TTM)
- 19.68
- P/B
- 0.92
- ROE
- 8.75%
- Dividend Yield
- 0.00%
- EBITDA
- ₹12.20 Cr
- 52W High
- ₹47.00
- 52W Low
- ₹16.20
- Day Range
- ₹27.55 – ₹27.55
- Volume
- 2,000
Peer Comparison
Commodities › Chemicals › Pesticides & Agrochemicals
| ₹529.00 | 22.09 | ₹43,728 Cr | 1.28 | 1.16% | 5.64% | 10.10% | ₹52,804 Cr | ₹2,323 Cr | |
| ₹2,187.00 | 28.48 | ₹33,248 Cr | 2.95 | 0.69% | 11.20% | 15.00% | ₹6,516 Cr | ₹1,164 Cr | |
| ₹328.10 | 28.24 | ₹15,980 Cr | 4.43 | 0.41% | 17.60% | 23.50% | ₹3,192 Cr | ₹581 Cr | |
| ₹3,249.90 | 19.95 | ₹14,602 Cr | 4.92 | 4.57% | 23.70% | 29.10% | ₹5,595 Cr | ₹733 Cr | |
| ₹677.95 | 9.77 | ₹6,015 Cr | 1.88 | 2.23% | 23.20% | 30.20% | ₹5,357 Cr | ₹626 Cr | |
| ₹942.75 | 15.83 | ₹4,217 Cr | 2.50 | 0.21% | 18.50% | 23.80% | ₹1,953 Cr | ₹268 Cr | |
| ₹189.67 | 17.23 | ₹3,734 Cr | 1.68 | 1.58% | 10.20% | 14.10% | ₹2,962 Cr | ₹214 Cr | |
Ambey Laboratories (this company) | ₹27.55 | 19.68 | ₹78 Cr | 0.92 | 0.00% | 8.75% | 9.97% | ₹132 Cr | ₹4 Cr |
| ₹27.55 | — | — | — | — | 6.51% | 7.99% | — | — | |
| Median 9 companies | ₹529.00 | 19.82 | ₹10,309 Cr | 2.19 | 0.93% | 11.20% | 15.00% | ₹4,275 Cr | ₹604 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
Data confidence 98/100
Category scores
- Quality
- 30
- Poor
- Returns, margins, earnings quality 22% weight
- Valuation
- 39
- Weak
- Cheap vs sector & own history 24% weight
- Growth
- 39
- Weak
- Sales & profit trajectory 9% weight
- Financial Health
- 50
- Average
- Solvency, leverage, coverage 9% weight
- Momentum
- 60
- Good
- Trend strength, vol-adjusted 12% weight
- Ownership
- 50
- Average
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
1- Stock is trading at 0.68 times its book value
Weaknesses
3- Though the company is reporting repeated profits, it is not paying out dividend
- Debtor days have increased from 60.5 to 112 days.
- Working capital days have increased from 64.4 days to 126 days
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Strong Bullish | 3 | 6 | 10 |
| Oscillators | Bullish | 1 | 6 | 2 |
| Moving Averages | Strong Bullish | 2 | 0 | 8 |
Oscillators
Bullish
Overall
Strong Bullish
Moving Averages
Strong Bullish
Key readings
- RSI (14)
- 53.77
- Neutral
- MACD (12,26,9)
- −0.10
- Bullish
- SMA (50)
- 26.55
- Bullish
- SMA (200)
- 27.77
- Bearish
As of
Growth Rate
From the financial statements below. 3Y: compound annual growth to Mar 2025; 1Y: fiscal year to Mar 2025 against Mar 2024.
Revenue
| 3Y | +15.51% |
|---|---|
| 1Y | +9.17% |
Net profit
| 3Y | +7.72% |
|---|---|
| 1Y | −37.50% |
Operating cash flow
| 3Y | Turned negative |
|---|---|
| 1Y | Outflow widened by ₹21 Cr |
Operating margin· change in pp
| 3Y | −4.13 pp |
|---|---|
| 1Y | +0.13 pp |
Trailing twelve months: The latest quarterly results are more than a year old.
Revenue by year
| Mar 2021 | ₹82.00 Cr |
|---|---|
| Mar 2022 | ₹85.00 Cr |
| Mar 2023 | ₹105 Cr |
| Mar 2024 | ₹120 Cr |
| Mar 2025 | ₹131 Cr |
Net profit by year
| Mar 2021 | ₹10.00 Cr |
|---|---|
| Mar 2022 | ₹4.00 Cr |
| Mar 2023 | ₹5.00 Cr |
| Mar 2024 | ₹8.00 Cr |
| Mar 2025 | ₹5.00 Cr |
Half-yearly Results
₹ CrResults for the period ended Mar 2026 were due by 30 May 2026 and are not in this table yet.
| Particulars | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|
| Sales | 60 | 68 | 64 | 68 |
| Expenses | 56 | 62 | 60 | 62 |
| Operating Profit | 4 | 6 | 4 | 6 |
| OPM % | 7% | 9% | 6% | 9% |
| Other Income | 1 | 1 | 1 | 0 |
| Interest | 1 | 2 | 1 | 1 |
| Depreciation | 1 | 1 | 2 | 2 |
| PBT | 3 | 4 | 2 | 3 |
| Tax % | 33% | 18% | 25% | 13% |
| Net Profit | 2 | 3 | 2 | 3 |
| EPS (₹) | 0.94 | 1.19 | 0.73 | 1.05 |
Profit & Loss
₹ Cr| Particulars | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|
| Sales | 82 | 85 | 105 | 120 | 131 | 132 |
| Expenses | 72 | 74 | 97 | 111 | 122 | 122 |
| Operating Profit | 10 | 10 | 8 | 9 | 10 | 10 |
| OPM % | 12% | 12% | 7% | 8% | 7% | 7% |
| Other Income | 1 | 1 | 3 | 1 | 2 | 1 |
| Interest | 4 | 3 | 2 | 2 | 3 | 2 |
| Depreciation | 3 | 3 | 3 | 2 | 3 | 4 |
| PBT | 3 | 5 | 6 | 6 | 6 | 5 |
| Tax % | −235% | 26% | 5% | −40% | 21% | — |
| Net Profit | 10 | 4 | 5 | 8 | 5 | 4 |
| EPS (₹) | 211 | 20.11 | 29.52 | 4.13 | 1.92 | 1.78 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
₹ Cr| Particulars | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|
| Equity Capital | 5 | 18 | 18 | 19 | 25 | 25 |
| Reserves | −13 | 1 | 1 | 13 | 51 | 67 |
| Borrowings | 33 | 18 | 14 | 30 | 41 | 40 |
| Other Liabilities | 20 | 19 | 21 | 18 | 10 | 9 |
| Total Liabilities | 45 | 56 | 54 | 79 | 127 | 140 |
| Fixed Assets | 16 | 25 | 25 | 24 | 23 | 22 |
| CWIP | 1 | 0 | 0 | 4 | 16 | 17 |
| Investments | 0 | 0 | 1 | 1 | 0 | 0 |
| Other Assets | 28 | 31 | 28 | 51 | 88 | 101 |
| Total Assets | 45 | 56 | 54 | 79 | 127 | 140 |
Cash Flow
₹ Cr| Particulars | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Operating | 3 | 6 | 10 | −13 | −34 |
| Investing | −1 | −1 | −4 | −5 | −14 |
| Financing | −1 | −5 | −6 | 18 | 48 |
| Net Cash Flow | 0 | 0 | 0 | 0 | 0 |
| Free Cash Flow | 2 | 5 | 7 | −18 | −48 |
| CFO/OP | 23 | 47 | 120 | −131 | −347 |
Ratios
| Particulars | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Debtor Days | 31 | 37 | 12 | 57 | 112 |
| Inventory Days | — | — | 78 | 75 | 99 |
| Days Payable | — | — | 74 | 54 | 22 |
| Cash Conversion Cycle | 31 | 37 | 17 | 78 | 189 |
| Working Capital Days | −10 | 11 | 18 | 49 | 126 |
| ROCE % | — | 25% | 22% | 18% | 10% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Ambey Laboratories insights
29 extracted metrics across FY21–FY26.
Documents
Frequently Asked Questions about Ambey Laboratories
What does Ambey Laboratories Ltd do?
Where is Ambey Laboratories Ltd (DHANSA) listed?
Which sector does Ambey Laboratories Ltd belong to?
What is the PE ratio of Ambey Laboratories Ltd?
What is the 52-week high and low of Ambey Laboratories Ltd?
What is the Return on Equity (ROE) of Ambey Laboratories Ltd?
Company Information
Incorporated in 1985, Ambey Laboratories Ltd is in the business of manufacturing and distribution of agro and home hygiene products.
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/AMBEY.md for Ambey Laboratories Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.